Ozempic linked to lower Alzheimer's risk in people with Type 2 diabetes

Original Article ↗ Hacker News Discussion ↗

Study Findings and Mechanism Questions

  • Summary: Semaglutide users with Type 2 diabetes showed substantially lower Alzheimer’s risk vs other diabetes drugs, especially insulin (70% lower risk).
  • Several commenters ask whether the effect is from semaglutide itself or from indirect effects: weight loss, reduced caloric intake, or improved glucose control.
  • Some note that similar benefits might not extend to thin, metabolically healthy people; others point out ongoing trials in non-obesity conditions (Alzheimer’s, Parkinson’s, addiction, NASH, PCOS, CVD).
  • The idea of Alzheimer’s as “type 3 diabetes” is raised, but one commenter pushes back on that framing.

Causality, Confounding, and Evidence Quality

  • Concerns about non-randomized, retrospective EHR analysis: selection bias (e.g., people closer to Alzheimer’s onset might be less likely to seek or get semaglutide).
  • Calls for more randomized, disease-focused trials and independent replication before strong conclusions.
  • One commenter flatly calls the publication “bogus” and points to broader uncertainty in Alzheimer’s research.

Benefits, Side Effects, and Long‑Term Risk

  • Enthusiastic group: GLP‑1s are described as potentially “the most important drug of our lifetime,” with large effects on obesity, diabetes, cardiovascular risk, and possibly addictions.
  • Personal anecdotes:
    • Major weight loss with reduced “food noise” and easier “intuitive eating.”
    • Dramatic reduction or cessation of heavy alcohol use without cravings.
  • Skeptical group:
    • Worries about long‑term, high‑dose use for weight loss vs older, lower‑dose diabetes regimens.
    • Known issues: nausea, GI effects, rare gastroparesis, possible thyroid cancer signal in animals, muscle/bone loss with rapid weight loss, occasional mood issues.
    • Some expect a future “other shoe dropping,” referencing the history of failed weight‑loss drugs. Others respond that GLP‑1s differ mechanistically and have ~15–20 years of class experience.

Obesity, Personal Responsibility, and Culture

  • Intense debate over “just eat less and exercise” vs biology, environment, and food industry influences.
  • Multiple commenters emphasize that lifestyle advice alone has poor real-world success for significant, sustained weight loss.
  • Others argue culture, food systems, and individual responsibility should be the primary levers, not chronic drug use.

Cost, Access, and Policy

  • High US prices (~$1,000/month) criticized as life‑and‑death gatekeeping, especially given much lower prices abroad.
  • Ideas floated: government patent purchase, compulsory licensing, or “national security” framing; counterpoints note huge acquisition costs and upcoming patent expirations.

Data and Privacy

  • The study’s 116M‑patient EHR dataset is not public; likely comes from commercial aggregators.
  • Some express strong discomfort with large, cloud‑hosted medical data despite HIPAA assurances.